Morphic’s lead product is an oral small molecule inhibitor that is a potential inflammatory bowel disease treatment, according to a July 8 news release from Eli Lilly. The biopharmaceutical business is also testing therapies for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
Both company’s boards have approved the transaction, which is expected to finalize in the third quarter of 2024.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
